These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11470383)

  • 1. SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia-related health.
    Rabeneck L; Cook KF; Wristers K; Souchek J; Menke T; Wray NP
    J Clin Epidemiol; 2001 Aug; 54(8):755-65. PubMed ID: 11470383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy.
    Rabeneck L; Wristers K; Goldstein JL; Eisen G; Dedhiya SD; Burke TA
    Am J Gastroenterol; 2002 Jan; 97(1):32-9. PubMed ID: 11808967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of upper endoscopy on satisfaction in patients with previously uninvestigated dyspepsia.
    Rabeneck L; Wristers K; Souchek J; Ambriz E
    Gastrointest Endosc; 2003 Mar; 57(3):295-9. PubMed ID: 12612505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double blind, randomized, placebo-controlled trial of proton pump inhibitor therapy in patients with uninvestigated dyspepsia.
    Rabeneck L; Souchek J; Wristers K; Menke T; Ambriz E; Huang I; Wray N
    Am J Gastroenterol; 2002 Dec; 97(12):3045-51. PubMed ID: 12492188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring dyspepsia-related health in randomized trials: the Severity of Dyspepsia Assessment (SODA) and its use in treatment with NSAIDs and COX-2-specific inhibitors.
    Rabeneck L
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii32-9. PubMed ID: 14585916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials.
    Veldhuyzen van Zanten SJ; Chiba N; Armstrong D; Barkun AN; Thomson AB; Mann V; Escobedo S; Chakraborty B; Nevin K
    Aliment Pharmacol Ther; 2006 Feb; 23(4):521-9. PubMed ID: 16441473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcuma longa Linn versus omeprazole in treatment of functional dyspepsia: A randomized, double-blind, placebo-controlled trial.
    Yongwatana K; Harinwan K; Chirapongsathorn S; Opuchar K; Sanpajit T; Piyanirun W; Puttapitakpong C
    J Gastroenterol Hepatol; 2022 Feb; 37(2):335-341. PubMed ID: 34652861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia.
    Koskenpato J; Farkkilä M; Sipponen P
    Am J Gastroenterol; 2001 Oct; 96(10):2866-72. PubMed ID: 11693319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies).
    Talley NJ; Meineche-Schmidt V; Paré P; Duckworth M; Räisänen P; Pap A; Kordecki H; Schmid V
    Aliment Pharmacol Ther; 1998 Nov; 12(11):1055-65. PubMed ID: 9845395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected].
    Mason I; Millar LJ; Sheikh RR; Evans WM; Todd PL; Turbitt ML; Taylor MD
    Aliment Pharmacol Ther; 1998 Mar; 12(3):263-71. PubMed ID: 9570261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group.
    Blum AL; Arnold R; Stolte M; Fischer M; Koelz HR
    Gut; 2000 Oct; 47(4):473-80. PubMed ID: 10986206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyspepsia: how should we measure it?
    Kuykendall DH; Rabeneck L; Campbell CJ; Wray NP
    J Clin Epidemiol; 1998 Feb; 51(2):99-106. PubMed ID: 9474070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials.
    Peura DA; Kovacs TO; Metz DC; Siepman N; Pilmer BL; Talley NJ
    Am J Med; 2004 Jun; 116(11):740-8. PubMed ID: 15144910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does endoscopy have a positive impact on quality of life in dyspepsia?
    Wiklund I; Glise H; Jerndal P; Carlsson J; Talley NJ
    Gastrointest Endosc; 1998 Jun; 47(6):449-54. PubMed ID: 9647367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomised trial with a six month follow up.
    Koelz HR; Arnold R; Stolte M; Fischer M; Blum AL;
    Gut; 2003 Jan; 52(1):40-6. PubMed ID: 12477757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study.
    Meineche-Schmidt V; Talley NJ; Pap A; Kordecki H; Schmid V; Ohlsson L; Wahlqvist P; Wiklund I; Bolling-Sternevald E
    Scand J Gastroenterol; 1999 Jun; 34(6):566-74. PubMed ID: 10440605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients.
    Färkkilä M; Sarna S; Valtonen V; Sipponen P;
    Scand J Gastroenterol; 2004 Apr; 39(4):327-35. PubMed ID: 15125464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies.
    Talley NJ; Lauritsen K
    Gut; 2002 May; 50 Suppl 4(Suppl 4):iv36-41. PubMed ID: 11953346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the symptomatology and quality of life in functional dyspepsia before and after Helicobacter pylori eradication treatment].
    Ladrón de Guevara L; Peña-Alfaro NG; Padilla L; Lichtinger A; Figueroa S; Shapiro I; Rubinstein M; Di Silvio M
    Rev Gastroenterol Mex; 2004; 69(4):203-8. PubMed ID: 15765971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
    Rabeneck L; Goldstein JL; Vu A; Mayne TJ; Rublee DA
    Am J Gastroenterol; 2005 May; 100(5):1043-50. PubMed ID: 15842577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.